TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03164642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA with Feedback
Description: The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LENA no feedback
Description: The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
Study: NCT02736617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT00193453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 30min IV, Day 1 \& 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30mg/m2, 30min IV, day 1 \& 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 \& 15, all subsequent cycles 250mg/m2 IV day 1, 8, \& 15
Study: NCT01533259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
Study: NCT04272229

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognition
Description: Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognition
Description: Cognition tests will be performed with questionnaires, which will be applied to the main investigator. Stroop Color test, digit symbol substitution test, Addenbrooke's cognitive examination 3, mini-mental state examination, Montreal Cognitive Assessment, Trail Making Test A e B and Reaction time test will be performed to check the cognition in all volunteers.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sympathetic Nervous System
Description: The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sympathetic Nervous System
Description: The sympathetic activation will be evaluated by heart rate variability. Volunteers will have their hear rate recorded by a frequencymeter and the R-R interval will be analyzed to ch check the central nervous system activation during all cognitive tests.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Concentratio and Attention
Description: Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
Study: NCT04560881

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine
Description: Immunization schedule: 2-doses of investigational vaccine or placebo are inoculated to the deltoid muscle of the upper arm according to the immunization schedule of Day 0, 21.
Study: NCT00107887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TST (tuberculin skin test)
Description: Clinics will be trained in the use of TST for assessing exposure to TB
Study: NCT04272229

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Concentratio and Attention
Description: Concentration and attention measures will be recorded with the MindWave headset during all cognitive tests. The EEG will be recorded with the MindWave and then alfa wave will be analized to check the attention and concentration levels.
Study: NCT00819039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant administered orally or intraveously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant administered orally or intraveously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron administered intravenously.
Study: NCT03045172

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: PRP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT03366246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine / Prilocaine Cream
Description: according randomized this side received placebo or active product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: according randomized this side received placebo or active product
Study: NCT03694704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FineHearing strategy
Description: Cochlear implant with FineHearing strategy
Study: NCT03442452

Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Decision Aid Tool
Description: The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
Study: NCT00909844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin (I.N.N.)
Description: Decapeptyl® SR 11.25mg
Study: NCT03217409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin+Ezetimibe
Description: Rosuvastatin 5mg+Ezetimibe 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 5Mg Tablet
Study: NCT00694772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery-tonsillectomy
Description: standard of care electrocautery tonsillectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coblation-tonsillotomy
Description: use of Arthrocare Coblation Technology to perform tonsillotomy
Study: NCT02605330

Intervention type: PROCEDURE
Intervention: Fibrinogen plasma level
Description: At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.

Intervention type: PROCEDURE
Intervention: Fibrinogen plasma level
Description: At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.

Intervention type: PROCEDURE
Intervention: Fibrinogen plasma level
Description: At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
Study: NCT03581006

Intervention type: DIETARY_SUPPLEMENT
Intervention: Low-Calorie Mediterranean Diet
Description: Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity

Intervention type: COMBINATION_PRODUCT
Intervention: Technology based monitoring and behavioral participation
Description: Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary

Intervention type: OTHER
Intervention: Usual care group
Description: Control group, who will receive no dietary or behavioral intervention during the trial
Study: NCT04653311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina®
Description: Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
Study: NCT03807635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ergoLance safety lancet
Description: The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acti-Lance safety lancet
Description: The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
Study: NCT00601055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving-Rx Adherence (PSA)
Description: In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PID-C
Description: In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
Study: NCT03413514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NACT
Description: SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0\<n\<8)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SDM
Description: Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical surgery with D2 lymph node dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT
Description: SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0\<n\<8)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
Study: NCT04324749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted peanuts (group A)
Description: After 2 weeks following a peanut-free diet, the participants of this group consume 25 g/ day of whole skin roasted peanuts (RP) within the habitual diet during 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut butter (group B)
Description: After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of peanut butter (PB) within the habitual diet during 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (group C)
Description: After 2 weeks following a peanut-free diet, the participants of this group consume 2 tbsp/ day (32 g/ day) of control supplement (containing the same proportion of macronutrients as peanuts and peanut butter) within the habitual diet during 6 months.
Study: NCT01925443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Will be performed irradiation with low-intensity laser in quadriceps muscle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Will be performed irradiation with low-intensity laser in quadriceps muscle
Study: NCT00605683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide (as add-on therapy)
Description: Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Safinamide (as add-on therapy)
Description: Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Safinamide (as add-on therapy)
Description: Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Study: NCT02936947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Percussive Ventilation
Description: High Frequency Percussive Ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Percussive Ventilation
Description: High Frequency Percussive Ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free breathing
Description: Free breathing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Breathing Control
Description: Active Breathing Control
Study: NCT02964624

Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
Study: NCT02965924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5%
Description: Instilling phenylephrine 2.5% eye drop
Study: NCT03343548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: 2cc of magnesium sulfate ( 50%) will be administered epidurally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2cc of normal saline will be administered epidurally
Study: NCT02282462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reg Pressure
Description: Regulated Suction using the Thopaz+ digital chest drainage device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reg Pressure
Description: Regulated Suction using the Thopaz+ digital chest drainage device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unreg Pressure
Description: Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unreg Pressure
Description: Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
Study: NCT03154853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: short foot exercise
Description: Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
Study: NCT02815878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhance Wellness
Description: A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhance Wellness
Description: A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
Study: NCT03325530

Intervention type: BEHAVIORAL
Intervention: Focus Group with Participants
Description: Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
Study: NCT02864758

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablets, 20mg once daily

Intervention type: DRUG
Intervention: Vitamin K antagonists
Description: Tablets, dose is based on International Normalized Ratio

Intervention type: DRUG
Intervention: dabigatran (Pradaxa)
Description: Tablets, 150 mg twice daily
Study: NCT01048320

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total.
Study: NCT02282462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Suction (Dig)
Description: Thopaz+ digital chest drainage device set at -20cmH2O at the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Suction (Trad)
Description: Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Drainage (Dig)
Description: Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Drainage (Trad)
Description: Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')
Study: NCT03955172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
Study: NCT00289211

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Study: NCT02151721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, gefitinib
Description: Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
Study: NCT03668106

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sperm processing method
Description: different sperm processing method for selcting most proper sperm for ICSI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sperm processing method
Description: different sperm processing method for selcting most proper sperm for ICSI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sperm processing method
Description: different sperm processing method for selcting most proper sperm for ICSI
Study: NCT01726166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapubic Aspiration
Description: Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Catheterization
Description: Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
Study: NCT01033136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Channel Exposure Therapy - Veterans
Description: MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
Study: NCT00017251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00243243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIIa
Description: intravenous infusion of Factor VIIa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of placebo (sterile water)
Study: NCT03477656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large volume specific immunoadsorption
Description: 1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Filtration Plasmapheresis
Description: 1 to 5 sessions of double filtration plasmapheresis
Study: NCT00454298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGG-523 (Aggrecanase Inhibitor)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGG-523 (Aggrecanase Inhibitor)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGG-523 (Aggrecanase Inhibitor)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGG-523 (Aggrecanase Inhibitor)